Infection treatment biotech Ruthigen sets terms for $20 million IPO


Shutterstock photo

Ruthigen, an early stage biotech developing therapeutics to prevent and treat infection in surgical procedures, announced terms for its IPO on Wednesday. The Santa Rosa, CA-based company plans to raise $20 million by offering 1.5 million shares at a price range of $12 to $14. At the midpoint of the proposed range, Ruthigen would command a market value of $46 million.

Ruthigen, which was founded in 2013, plans to list on the NASDAQ under the symbol RTGN. Ruthigen initially filed confidentially on May 24, 2013. Aegis Capital is the sole bookrunner on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by